RNS Number:9232T
VASTox plc
28 March 2007

                                   VASTox plc

                          ("VASTox" or "the Company")



                             DIRECTOR SHAREHOLDING





Oxford, UK, 28 March 2007 - VASTox plc (AIM: VOX) announces that a total of
8,807 Ordinary Shares of 10 pence per share were purchased today by three of the
Company's Non-executive Directors pursuant to the terms of the Non-executive
Share Ownership Scheme, which took effect on 1 February 2007 and was announced
on 27 March 2007.



The details of the transaction are set out below:


Director                    Number of     Price        Aggregate number of      % of Ordinary Shares in
                             shares                      Ordinary Shares       issue beneficially owned
                            purchased                  beneficially owned       following the purchase
                                                     following the purchase
Barry Price                   2,077       #1.29               2,077                      0.1%
David Norwood                 6,037       #1.29               6,037                      0.1%
Sir Brian Richards             693        #1.29                693                       0.1%



                                    - ends -



For more information, please contact:


VASTox

Steven Lee, PhD, Chief Executive Officer            Tel: +44 (0)1235 443951
Darren Millington, Chief Financial Officer


Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray        Tel: +44 (0)207 638 9571



About VASTox plc



VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.



VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.



VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.



The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX



Further information about the company is available at www.vastox.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RDSBLGDXUDDGGRI
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vox Valor Capital Charts.
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vox Valor Capital Charts.